Neil D. Gross, MD, FACS, is head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at MD Anderson.
At this year’s European Society for Medical Oncology annual meeting, study results were presented on the use of neoadjuvant cemiplimab in the setting of stage II to IV resectable cutaneous squamous cell carcinoma (cSCC). Lead investigator Neil D. Gross, MD, FACS, head and neck surgeon and director of clinical research in the Department of Head and Neck Surgery at MD Anderson, recently discussed these results with The American Journal of Managed Care®.
Transcript
Can you discuss your study presented at ESMO on cemiplimab and why the monoclonal antibody is important in making progress against cSCC?
I’m pleased to discuss our trial on neoadjuvant immunotherapy in stage II to IV cutaneous squamous cell carcinoma. It’s important to highlight up front that this is in resectable disease. Immunotherapy is approved for use in unresectable, or metastatic, cutaneous squamous cell carcinoma, but this is the first trial, other than a pilot trial we completed, to test immunotherapy in the neoadjuvant setting in resectable cutaneous squamous cell carcinoma.
The pilot study was performed here at MD Anderson; it included only 20 patients with resectable but advanced-stage disease, where the intent was really not to influence treatment. In that study, patients had to undergo the full extent of surgery after neoadjuvant therapy as they would have at baseline. We were really astounded to see the responses to treatment in that pilot trial. Over half of the patients had a complete pathologic response to treatment, and based on the strength of those results, it prompted a multicenter confirmatory trial that was reported at ESMO and published in The New England Journal of Medicine.
That confirmatory trial was completed at over 20 centers in the United States, Australia, and Europe. It enrolled 79 patients; it included patients with stage II to stage IV resectable cutaneous squamous cell carcinoma. One important difference with this study, from the pilot trial, is that it allowed for smaller surgery as patients responded to immunotherapy.
Patients in this study were allowed to have less-invasive surgery if it was oncologically appropriate. Surgeons were still required, and encouraged, to remove all gross tumor, but if they felt safe, they could preserve functionally important structures. We had several patients in the trial where that was the case. We highlighted 2 patients in the manuscript who were recommended for up-front orbital exenteration as part of their surgery and planned adjuvant radiation. In both cases, they had a partial response on imaging, but a complete pathologic response at the time of surgery, sparing the eye, and then have gone on to follow up. So very, very encouraging results.
And in the multicenter trial, we confirmed what we saw in the pilot trial, which is that over half of the patients had a complete pathologic response—no residual viable tumor—when it came time for surgery, and another 10 patients out of 79 had a near complete pathologic response. So less than 10% residual viable tumor cells in the specimens. So very, very encouraging early results from this trial.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More